Study of DACA (XR5000) as a Cancer Treatment
Author Information
Author(s): Twelves C J, Gardner C, Flavin A, Sludden J, Dennis I, Bono J de, Beale P, Vasey P, Hutchison C, Macham M A, Rodriguez A, Judson I, Bleehen N M
Primary Institution: CRC Department of Medical Oncology, Alexander Stone Building, Glasgow, Bearsden, G61 1BD, UK
Hypothesis
Can DACA (XR5000) be safely administered to patients and what are its pharmacokinetics?
Conclusion
DACA was found to have a unique toxicity profile and showed no objective responses in patients.
Supporting Evidence
- DACA was administered to 41 patients at 11 different dose levels.
- The most common side effect was pain during the infusion.
- There was one minor response but no objective responses were observed.
- DACA's pharmacokinetics were linear and consistent across treatment days.
Takeaway
Doctors tested a new cancer drug called DACA on 41 patients, but it didn't work well and caused some unusual side effects.
Methodology
DACA was given as a 3-hour intravenous infusion on 3 successive days, repeated every 3 weeks.
Limitations
The study had a small sample size and only one minor response was observed.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website